VBIV - VBIワクチン （VBI Vaccines Inc.）

VBI Vaccines Inc. (VBIV)’s stock has witnessed a price hike of 4.83% from the previous close with its current price standing at $0.41. Its current price is -83.40% under its 52-week high of $2.47 and 13.89% more than its 52-week low of $0.36. Based on the past 30-day period, the stock price is -28.38% below […]

According to data from Benzinga Pro, during Q3, VBI Vaccines ''s (NASDAQ: VBIV ) reported sales totaled $317 thousand. Despite a 44.84% increase in earnings, the company posted a loss of $25.21 million. VBI Vaccines collected $346 thousand in revenue during Q2, but reported earnings showed a $45.70 million loss. What Is Return On Capital Employed? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth … Full story available on Benzinga.com

Health Canada has approved VBI Vaccines (VBIV) hepatitis B vaccine PreHevbrio.The approval is the fourth for the triple-antigen shot.

CEPI and VBI expand scope of partnership to target multiple coronavirus threats Vaccine platform presents multiple antigens, mimicking natural form of the virus The Coalition for Epidemic Prepared…

CEPI and VBI expand scope of partnership to target multiple coronavirus threats Vaccine platform presents multiple antigens, mimicking natural form of the virus OSLO, Norway & CAMBRIDGE, Mass. — The Coalition for Epidemic Preparedness Innovations (CEPI) is expanding its world-leading portfolio of potential variant-proof coronavirus vaccines in a deal with VBI Vaccines Inc. (Nasdaq: VBIV) […]

VBI Vaccines (VBIV) is trading ~3% higher in the premarket Friday after the commercial stage vaccine maker announced that an expert panel of the European Medicines Agency ((EMA)) issued…

Cambridge, Massachusetts-based vaccine maker VBI Vaccines (VBIV) announced on Wednesday that an expert panel of the U.S

During the last session, VBI Vaccines Inc. (NASDAQ:VBIV)’s traded shares were 1.85 million, with the beta value of the company hitting 1.91. At the end of the trading day, the stock’s price was $1.44, reflecting an intraday loss of -5.88% or -$0.09. The 52-week high for the VBIV share is $4.31, that puts it down … VBI Vaccines Inc. (NASDAQ: VBIV)’s Stock Is Down -60.98% Since The Beginning Of The Year, Likely To Sustain The Trend In 2022 Read More »

VBI Vaccines Inc. (VBIV) shares closed today at 1.4% above its 52 week low of $2.09, giving the company a market cap of $545M. The stock is currently down 9.4% year-to-date, down 34.2% over the past 12 months, and down 37.6% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 31.5% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -24.7% The company's stock price performance over the past 12 months beats the peer average by -15.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

Investors almost seemed ready to take profits once shares hit their highest level since February.

Data presented at The International Liver Congress The Annual Meeting of the European Association for the Study of the Liver, including: Brii Biosciences, VBI Vaccines.

(RTTNews) - VBI Vaccines Inc. (VBIV) announced positive Phase 1 data from its Phase 1/2 trial of the first of its enveloped virus-like particle or eVLP COVID-19 vaccine candidates, VBI-2902a, in healthy adults age 18-54 years of age. In Tuesday pre-market trade, VBIV was trading at $4.33 up $0.32 or 7.98%. The company noted that the 5µg dose

DURHAM, N.C. & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Brii Biosciences (Brii Bio) en VBI Vaccines Inc. (NASDAQ: VBIV) (VBI), kondigden vandaag de definitieve resultaten aan van een Fase 1b/2a studie met BRII-179 (VBI-2601), een nieuwe recombinante immunotherapeutische kandidaat op basis van eiwitten, bij patiënten met chronische hepatitis B-virus (HBV) infectie. De gegevens van de studie, die de veiligheid, antivirale activiteit en immunogeniciteit van BRII-179 (VBI-2601) alleen of ge